PTH:NSD-Invesco DWA Healthcare Momentum ETF (USD)

ETF | Health |

Last Closing

USD 46.83

Change

-0.29 (-0.62)%

Market Cap

USD 0.14B

Volume

0.02M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of at least 30 securities of companies in the healthcare sector that have powerful relative strength or momentum characteristics.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
IBB iShares Biotechnology ETF

-0.56 (-0.39%)

USD 7.19B
PPH VanEck Pharmaceutical ETF

-0.05 (-0.06%)

USD 0.67B
BBH VanEck Biotech ETF

+0.36 (+0.21%)

USD 0.43B
PSCH Invesco S&P SmallCap Health Ca..

-0.51 (-1.07%)

USD 0.18B
GNOM Global X Genomics & Biotechnol..

+0.03 (+0.28%)

USD 0.08B
FTXH First Trust Nasdaq Pharmaceuti..

-0.07 (-0.23%)

USD 0.02B
CNCR Loncar Cancer Immunotherapy ET..

-0.29 (-1.93%)

USD 0.01B

ETFs Containing PTH

DWTR 0.00 % 0.15 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.65% 100% F 73% C
Dividend Return 0.06% 20% F N/A F
Total Return 19.71% 100% F 72% C
Trailing 12 Months  
Capital Gain 45.07% 100% F 80% B-
Dividend Return 0.08% 17% F 1% F
Total Return 45.15% 100% F 80% B-
Trailing 5 Years  
Capital Gain 66.93% 100% F 77% C+
Dividend Return 0.09% 14% F N/A F
Total Return 67.02% 100% F 74% C
Average Annual (5 Year Horizon)  
Capital Gain 5.19% 88% B+ 54% F
Dividend Return 5.20% 75% C 51% F
Total Return 0.00% 13% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 34.08% 13% F 55% F
Risk Adjusted Return 15.25% 75% C 47% F
Market Capitalization 0.14B 50% F 44% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.